
ASH Curiosity Collection
Card 03 · Hb and Hct
Anemia is tracked by hemoglobin, P vera by hematocrit. Why?
The short answerHemoglobin or hematocrit? Two measurements. One physiological problem.
Hemoglobin and hematocrit usually rise and fall together. So why do we emphasize hemoglobin in anemia but hematocrit in polycythemia vera?
Explore the scienceAnemia: Hb
P vera: Hct
Why?
One physiological trade-off
The answer begins with a physiological trade-off. Blood must carry enough oxygen to nourish the tissues, but it must also flow easily enough to deliver that oxygen. Increasing the concentration of red cells helps accomplish the first task while progressively making the second more difficult.
- 1 / 3The oxygen delivery curve
- 2 / 3What limits oxygen delivery?
- 3 / 3From physiology to clinical practice
The oxygen delivery curve
Imagine plotting oxygen delivery against hematocrit, with hemoglobin/hematocrit (H/H) concentration increasing alongside it.
At very low H/H, blood flows relatively easily but carries too little oxygen. As hematocrit increases, more hemoglobin becomes available to transport oxygen, and oxygen delivery improves.
But the benefit cannot continue indefinitely. Increasing hematocrit also raises blood viscosity. As the blood becomes more resistant to flow, the advantage of carrying additional oxygen can eventually be outweighed by the reduction in blood flow.
The result is a conceptual inverted-U curve: oxygen delivery initially increases, reaches a maximum, and then declines. Somewhere between too few red cells and too many lies an optimal balance between oxygen-carrying capacity and blood flow.
The exact position of that optimum depends on physiological conditions. The curve illustrates a governing principle, not a single optimal hematocrit for every individual.
Oxygen delivery = blood flow × arterial oxygen content
Blood flow ∝ 1 / blood viscosity
Arterial oxygen content ∝ hemoglobin concentration
What limits oxygen delivery?
The two sides of the curve represent different physiological problems.
To the left of the optimum: hemoglobin is limiting.
In anemia, the blood contains too little hemoglobin to carry an adequate quantity of oxygen. Increasing hemoglobin generally improves oxygen-carrying capacity. Although viscosity also increases, that effect is not ordinarily the dominant limitation in this part of the curve.
This is why hemoglobin is the natural measurement to emphasize when considering anemia.
Near the optimum: neither extreme dominates.
In the broad middle region, oxygen-carrying capacity and blood flow are reasonably balanced. Hemoglobin and hematocrit ordinarily track one another, and either can provide a useful description of the circulating red-cell compartment.
Neither number, however, directly measures tissue oxygen delivery.
To the right of the optimum: viscosity becomes increasingly important.
As hematocrit rises, blood carries more hemoglobin but also becomes more viscous. Beyond the optimum, the resulting resistance to flow can outweigh the benefit of additional oxygen-carrying capacity.
In this region, hematocrit is a particularly relevant measurement because the fraction of blood occupied by red cells is a major determinant of viscosity.
The physiological lesson is that the importance of a measurement depends on what is limiting oxygen delivery. Drag the slider to explore the trade-off.
Increasing hematocrit improves oxygen content, but viscosity is rising too.
Too few red cells: oxygen content is low. Blood flows easily, but hemoglobin is limiting.Increasing hematocrit improves oxygen content, but viscosity is rising too.Viscosity is climbing steeply. The extra resistance to flow now outweighs the added oxygen content, so delivery falls.Illustrative physiological model. The optimal hematocrit varies with circulatory conditions and is not a clinical treatment threshold. As hematocrit increases, hemoglobin concentration is assumed to increase proportionally.
From physiology to clinical practice
Clinical practice reflects this distinction.
In anemia, transfusion decisions are guided principally by hemoglobin. This makes physiological sense: low oxygen-carrying capacity is the central concern. Hemoglobin-based transfusion thresholds have also been evaluated extensively in randomized clinical trials.
In polycythemia vera, treatment targets hematocrit. Elevated hematocrit increases blood viscosity and can contribute to impaired blood flow. The CYTO-PV trial demonstrated that maintaining hematocrit below 45%, rather than between 45% and 50%, reduces the combined risk of cardiovascular death or major thrombosis.
These choices are supported by clinical evidence, but they also have a coherent physiological rationale.
It is important not to confuse the two kinds of evidence. The optimal-hematocrit curve describes how oxygen-carrying capacity and viscosity can compete to determine oxygen delivery. It does not establish the clinical transfusion threshold in anemia or the hematocrit target in polycythemia vera.
Nor is thrombosis in polycythemia vera simply the result of reduced oxygen delivery. Its pathophysiology involves additional cellular and vascular mechanisms.
Left of the optimum
AnemiaOxygen-carrying capacity is limiting.
Emphasize Hb
Near the optimum
Normal rangeCapacity and flow are more balanced.
Hb or Hct can describe red-cell status
Right of the optimum
Excessive hematocritViscosity can become limiting.
Emphasize Hct
Test your curiosity
Pick the answer you think is right. Every choice explains itself, and you can try again.
A patient with polycythemia vera has become iron deficient from repeated phlebotomy. The red cells are small and pale. Hemoglobin is 13.5 g/dL and hematocrit is 47%. What does this mean?
In P vera, the danger is thickness, and hematocrit measures that. Small, pale cells hold less hemoglobin each, so hemoglobin can look reassuring while the hematocrit is above target.
Hematocrit tracks viscosity, which drives the clotting risk in P vera. With iron deficiency, hemoglobin lags behind hematocrit, which is one reason treatment targets hematocrit and not hemoglobin.
Iron would fuel the overactive marrow and push the hematocrit even higher. In P vera, mild iron deficiency from phlebotomy is usually accepted, unless it is causing symptoms.
What limits oxygen delivery depends on where you are on the curve.
In anemia, too little hemoglobin limits oxygen transport. At excessively high hematocrit, increased viscosity can restrict blood flow enough to outweigh the benefit of additional hemoglobin.
Clinical practice reflects this distinction. Transfusion decisions in anemia commonly use hemoglobin thresholds, while treatment of polycythemia vera targets hematocrit below 45%.
Both approaches have clinical trial support, although neither threshold represents a universally established physiological optimum.
Blood doping pushes hematocrit to the right. But what if exercise moves the curve itself?
During exercise, changes in blood flow and vascular resistance may shift the optimal hematocrit higher. Could that help explain why blood doping improves endurance?
Stay Updated
Get the latest case studies, tutorials, and hematology insights delivered monthly to your inbox